Yuma is developing innovative disease-modifying pharmaceutical compounds that target the tau pathway, a promising new approach to affect the disease progression of Alzheimer's disease and other neurodegenerative diseases.

About Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurological disorder that affects more than 24 million people worldwide. In the U.S., AD affects more than five million people and is the sixth leading cause of death, surpassing diabetes. The economic burden of AD patient care in the U.S. is greater than $100 billion per annum.

An early symptom of AD is the inability to acquire new memories. As the disease advances, symptoms become more severe and debilitating including: confusion, personality changes, anxiousness, irritability, and severe memory and intellectual disturbances. Eventually patients no longer function normally. The average Alzheimer's patient dies about 8 to 12 years after the initial diagnosis.

The cause and progression of AD is not well understood. Research indicates amyloid plaques and neurofibrillary tangles form in the brain of Alzheimer’s patients. Plaques are dense and toxic clumps of proteins that collect around neurons. Tangles occur when fibers inside neurons become twisted, also causing neurons to die. 

Currently there are four U.S. Food and Administration (FDA) approved drugs for AD. They include cholinesterase inhibitors  – donepezil, rivastigmine, galantamine and N-methyl-D-aspartate (NMDA) antagonist, memantine.  However, none of these drugs slow or prevent the progression of the disease.

Copyright 2011, Yuma Therapeutics Corporation